Yezhou Ding

Shanghai, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Difficulty in differentiating liver injury from an immune checkpoint inhibitor from chemotherapy.

Difficulty in differentiating liver injury from an immune checkpoint inhibitor from chemotherapy.

Journal: Frontiers in pharmacology

Published: June 23, 2024

Liver fibrosis is closely linked with metabolic-associated diseases in patients with autoimmune hepatitis.

Liver fibrosis is closely linked with metabolic-associated diseases in patients with autoimmune hepatitis.

Journal: Hepatology international

Published: June 11, 2024

The expression landscape and clinical significance of methyltransferase-like 17 in human cancer and hepatocellular carcinoma: a pan-cancer analysis using multiple databases.

The expression landscape and clinical significance of methyltransferase-like 17 in human cancer and hepatocellular carcinoma: a pan-cancer analysis using multiple databases.

Journal: Cancer cell international

Published: January 23, 2024

The safety concerns regarding immune checkpoint inhibitors in liver cancer patients rising mainly from CHB.

The safety concerns regarding immune checkpoint inhibitors in liver cancer patients rising mainly from CHB.

Journal: Frontiers in pharmacology

Published: February 12, 2023

The 20 years transition of clinical characteristics and metabolic risk factors in primary liver cancer patients from China.

The 20 years transition of clinical characteristics and metabolic risk factors in primary liver cancer patients from China.

Journal: Frontiers in oncology

Published: November 28, 2022

Combination of IL-34 and AFP improves the diagnostic value during the development of HBV related hepatocellular carcinoma.

Combination of IL-34 and AFP improves the diagnostic value during the development of HBV related hepatocellular carcinoma.

Journal: Clinical and experimental medicine

Published: September 24, 2021

A novel model based on qAnti-HBc and conventional biomarkers for identifying significant liver injury among CHB patients with ALT ≤ ULN.

A novel model based on qAnti-HBc and conventional biomarkers for identifying significant liver injury among CHB patients with ALT ≤ ULN.

Journal: Antiviral research

Published: September 14, 2021

AL amyloidosis with primary presentation of multiple serous cavity effusion and severe cholestasis: a case report and review of literature.

AL amyloidosis with primary presentation of multiple serous cavity effusion and severe cholestasis: a case report and review of literature.

Journal: BMC gastroenterology

Published: April 21, 2021

Anti-viral effect in chronic hepatitis B patients with normal or mildly elevated alanine aminotransferase.

Anti-viral effect in chronic hepatitis B patients with normal or mildly elevated alanine aminotransferase.

Journal: Antiviral research

Published: August 04, 2020

Circulating Receptor-Interacting Protein Kinase 3 Are Increased in HBV Patients With Acute-on-Chronic Liver Failure and Are Associated With Clinical Outcome.

Circulating Receptor-Interacting Protein Kinase 3 Are Increased in HBV Patients With Acute-on-Chronic Liver Failure and Are Associated With Clinical Outcome.

Journal: Frontiers in physiology

Published: February 26, 2020

Combination of inflammatory score/liver function and AFP improves the diagnostic accuracy of HBV-related hepatocellular carcinoma.

Combination of inflammatory score/liver function and AFP improves the diagnostic accuracy of HBV-related hepatocellular carcinoma.

Journal: Cancer medicine

Published: December 08, 2019

Long Non-coding RNA NEAT1 Alleviates Acute-on-Chronic Liver Failure Through Blocking TRAF6 Mediated Inflammatory Response.

Long Non-coding RNA NEAT1 Alleviates Acute-on-Chronic Liver Failure Through Blocking TRAF6 Mediated Inflammatory Response.

Journal: Frontiers in physiology

Published: April 21, 2019

Showing 1-12 of 14

Last Updated: 09/26/2026